News

Brickell Enters into a License Agreement for Exclusive Rights to BBI-3000, a Novel, Potent Topical/Oral Retinoid, Acting as a Highly Selective RXR Agonist, for the Treatment of Skin Conditions Responsive to Retinoid Therapy

By June 1, 2012 No Comments